Abstract Host factors that are involved in modulating cellular vesicular trafficking of virus progeny could be potential antiviral drug targets. ADP-ribosylation factors (ARFs) are GTPases that regulate intracellular vesicular transport upon GTP binding. Here we demonstrate that genetic depletion of ARF4 suppresses viral infection by multiple pathogenic RNA viruses including Zika virus (ZIKV), influenza A… Continue reading ARF4-mediated intracellular transport as a broad-spectrum antiviral target
Tag: Antivirals
Designing antivirals for shape-shifting viruses
Viruses, like those that cause COVID-19 or HIV, are formidable opponents once they invade our bodies. Antiviral treatments strive to block a virus or halt its replication. However, viruses are dynamic — constantly evolving and changing shape, which can make designing antiviral treatments a challenge.
Mpox: Better understanding of tecovirimat resistance
A virus originally found in animals, mpox — which causes the disease of the same name — is now circulating in humans. Since 2022, it has been the cause of major epidemics spreading outside endemic areas in Central and West Africa. Two hundred and fifteen cases of mpox infection were reported to Sant publique France… Continue reading Mpox: Better understanding of tecovirimat resistance
The antiviral BDGR-49 provides protection from lethal, neurotropic Venezuelan equine encephalitis virus intranasal infection in mice
Structural insights into tecovirimat antiviral activity and poxvirus resistance
Abstract Mpox is a zoonotic disease endemic to Central and West Africa. Since 2022, two human-adapted monkeypox virus (MPXV) strains have caused large outbreaks outside these regions. Tecovirimat is the most widely used drug to treat mpox. It blocks viral egress by targeting the viral phospholipase F13; however, the structural details are unknown, and mutations… Continue reading Structural insights into tecovirimat antiviral activity and poxvirus resistance
Targeting eEF1A reprograms translation and uncovers broad-spectrum antivirals against cap or m6A protein synthesis routes
Abstract Plitidepsin is an antitumoral compound safe for treating COVID-19 that targets the translation elongation factor eEF1A. Here we detect that plitidepsin decreases de novo cap-dependent translation of SARS-CoV-2 and non-viral RNAs but affects less than 13% of the host proteome, thus preserving cellular viability. In response to plitidepsin, cells upregulate EIF2AK3 and proteins that… Continue reading Targeting eEF1A reprograms translation and uncovers broad-spectrum antivirals against cap or m6A protein synthesis routes
Impact of hepatic steatosis on the efficacy of antiviral treatment for chronic hepatitis B and the establishment of predictive model: a cohort study
Metabolic dysfunction-associated steatotic disease (MASLD) and chronic hepatitis B (CHB) are prevalent liver disorders. Ongoing discussions investigate the impact of MASLD on the therapeutic outcomes of CHB. Continue reading on BioMed Central
Single-cell transcriptomics reveals a compartmentalized antiviral interferon response in the nasal epithelium of mice
Advances in antiviral strategies targeting mosquito-borne viruses: cellular, viral, and immune-related approaches
Mosquito-borne viruses (MBVs) are a major global health threat, causing significant morbidity and mortality. MBVs belong to several distinct viral families, each with unique characteristics. The primary famili… Continue reading on BioMed Central